Feb 24 2012
In this post in the Results for Development Institute's "Center for Global Health R&D Policy Assessment" blog, Project Director Jean Arkedis and Program Associate Edith Han interview Megumi Gordon, deputy director for malaria at the Clinton Health Access Initiative (CHAI), "to take an exclusive look into the [Affordable Medicines Facility for Malaria (AMFm)] and its innovative mechanism to increase access to antimalarials." Megumi discusses "AMFm's current status, early lessons, and the latest in the ongoing -- and sometimes contentious -- debate about whether to subsidize [artemisinin-based combination therapies (ACTs)] in the private sector" (2/22).
 This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
|
A promising new strategy for malaria drug development